Psilocybin is the primary psychoactive compound found in magic mushrooms. It is a prodrug that, when ingested, converts to psilocin, which directly interacts with serotonin receptors in the brain. Psilocybin is known for its profound hallucinogenic effects, altering perception, cognition, and mood. It has been associated with spiritual experiences, introspection, and enhanced creativity.
Psilocin is the active metabolite of psilocybin and is responsible for the psychedelic effects experienced after consuming magic mushrooms. Like psilocybin, it binds to serotonin receptors, particularly the 5-HT2A receptor, influencing neural activity and leading to altered states of consciousness. Psilocin is known for its capacity to induce vivid visual hallucinations, intensify emotions, and foster a sense of connectedness.
Baeocystin is a lesser-known tryptamine present in magic mushrooms, occurring alongside psilocybin and psilocin. It is structurally similar to psilocybin and is thought to contribute to the overall psychedelic experience, albeit to a lesser extent. Baeocystin's exact effects and mechanisms of action are still not fully understood, but it likely contributes to the unique psychological and perceptual effects of magic mushrooms.
Norbaeocystin is another tryptamine compound found in magic mushrooms, but its effects and pharmacology are less well-studied compared to psilocybin and psilocin. It is believed to be a metabolic byproduct of psilocybin and may have some psychoactive properties, although further research is needed to fully elucidate its role in the psychedelic experience.
Norpsilocin is a metabolite of psilocin, which is itself a metabolite of psilocybin. It is formed in the body after psilocin undergoes enzymatic processes. While it is structurally similar to psilocin, there is limited research on the specific effects and mechanisms of action of norpsilocin. It is believed that norpsilocin is stronger than psilocin and may contribute to the overall psychedelic experience induced by magic mushrooms.
Aeruganascin is structurally related to psilocybin and is believed to have psychoactive properties, although its specific effects and mechanisms of action are not yet well understood. Preliminary research suggests that it may interact with serotonin receptors in the brain, similar to other tryptamines, leading to altered states of consciousness and psychedelic experiences.